However, further investigation is required to examine whether anti-HER2 macromolecular monoclonal antibodies also enhance the efficacy of CDK 4/6 inhibitors combined with endocrine therapy in HR+/HER2-low breast cancer. Here, ERBB2 is linked to breast carcinoma.